Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 557 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Targeted prostate cancer screening: Are we there yet? October 20, 2021 Listening to Patient Narratives June 9, 2020 Ponatinib Effectively Treats Newly Diagnosed Acute Lymphoblastic Leukemia: The ASCO Plenary... February 14, 2023 Lutathera Shows Promise as Part of Initial Therapy for Some Neuroendocrine... March 1, 2024 Load more HOT NEWS Five Questions With…Amber. Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk... ΠΟΝΟΣ New Study Shows Intermittent Fasting May Reduce Breast Cancer Risk and...
